Welcome to our dedicated page for Kamada news (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada stock.
Kamada Ltd. develops, produces and markets specialty plasma-derived therapeutics and other biopharmaceutical products for rare and serious conditions. News about KMDA commonly covers financial results and guidance, commercial performance of products such as KAMRAB, GLASSIA, HEPAGAM, VARIZIG, WINRHO and CYTOGAM, and supply arrangements for blood-product markets.
Company updates also address plasma collection operations, including FDA-cleared facilities in Texas, product distribution activity, dividend policy and withholding-tax procedures for ordinary-share distributions. Kamada is traded on Nasdaq and the Tel Aviv Stock Exchange.
Kamada (NASDAQ: KMDA) announced a new three-year agreement to supply normal source plasma from its FDA-approved collection centers in Houston and San Antonio, Texas, to a leading biopharmaceutical company focused on plasma-derived therapies. The agreement is expected to generate approximately $50 million in revenue over three years, with initial commercial sales anticipated in the fourth quarter of 2026.
Each Texas center is designed for a planned capacity of about 50,000 liters of plasma per year at full capacity, covering both normal source and specialty plasma. According to Kamada, this supply agreement supports its vertical-integration strategy, aligns with its multi-year revenue growth objectives, and the expected Q4 2026 sales are already included in its current full-year revenue guidance.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA) reported new data from an Investigator-Initiated Study of CYTOGAM (CMV immune globulin) in cytomegalovirus (CMV) high‑risk lung transplant recipients, presented as three posters at the 2026 ISHLT annual meeting in Toronto.
According to Kamada, retrospective clinical analyses suggested that patients who did not receive CMVIG prophylaxis had worse outcomes than those who did, and translational work showed less activated innate immune cells in CMVIG‑treated patients. A non‑clinical in‑vivo model indicated that CMVIG exposure blunted lung injury and improved mortality. Kamada noted these findings, together with a prior five‑year, 324‑patient retrospective study, may support increased CYTOGAM utilization as part of multimodality CMV prophylaxis in high‑risk lung transplant populations.
Kamada (NASDAQ: KMDA) received FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) rabies virus neutralization laboratory at its Beit Kama, Israel plant. The lab expands Anti-Rabies potency testing for KEDRAB and KAMRAB, Kamada’s leading franchise with 2025 sales over $70 million.
The RFFIT lab is part of Kamada’s Quality Control network, is among a limited number of global facilities able to run this gold-standard test, and was also approved by Health Canada and the Israeli Ministry of Health.
Kamada (NASDAQ:KMDA) reported Q1 2026 revenue of $45.2M, up 3% year-over-year, net income of $4.1M, up 4%, and adjusted EBITDA of $11.6M with a 26% margin.
The company reaffirmed 2026 guidance of $200M–$205M revenue and $50M–$53M adjusted EBITDA, highlighted FDA approval of its San Antonio plasma center, and paid a $0.25-per-share dividend totaling about $14.4M.
Kamada (NASDAQ: KMDA) will release first quarter 2026 financial results for the period ended March 31, 2026, before U.S. markets open on May 13, 2026. Management will host an investor conference call on May 13 at 8:30am ET and a live webcast will be available.
Dial-in numbers and conference ID 13760232 are provided for U.S., Israel, and international participants; the call will be webcast at the company's public webcast link.
Kamada (NASDAQ: KMDA) obtained an Israel Tax Authority ruling for its previously announced $0.25 per-share cash dividend (approximately $14.4 million), payable April 7, 2026 to shareholders of record March 23, 2026. The Company will withhold 25% initially; Treaty-state Nasdaq shareholders may apply for reduced withholding or exemption by May 9, 2026.
The Tax Agent is IBI Trust Management; full procedures, documentation requirements, and timing for refunds to eligible shareholders are specified in the Ruling.
Kamada (NASDAQ: KMDA) announced FDA approval of its plasma collection center in San Antonio, Texas, cleared to commence commercial sales of normal source plasma as of March 26, 2026.
The 11,100 sq ft facility supports up to 50 donor beds, has planned capacity of ~50,000 liters/year and is expected to generate $8 million to $10 million annually at full capacity. Kamada said it will seek subsequent EMA inspection/approval for the site.
Kamada (NASDAQ: KMDA) reported record 2025 results: $180.5M revenue (+12% YoY), $42.0M adjusted EBITDA (+23% YoY) and $20.2M net income (+40% YoY). The company generated $25.5M cash from operations and ended 2025 with $75.5M cash. Kamada affirmed 2026 guidance of $200M–$205M revenue and $50M–$53M adjusted EBITDA, adopted an annual cash dividend of $0.25 per share, and announced strategic focus on commercial expansion, plasma collection ramp-up and M&A.
Kamada (NASDAQ: KMDA) declared a cash dividend of $0.25 per share (approx. NIS 0.77), totaling about $14.4 million. The dividend is payable on April 6, 2026 to shareholders of record as of March 23, 2026.
The payment follows the Board's newly adopted annual cash dividend policy, under which the company intends to distribute at least 50% of annual net income, subject to Board discretion and applicable Israeli Companies Law tests. The company reported record revenue and profitability for full-year 2025 and will withhold tax under Israeli law; a tax ruling for non‑Israeli shareholders has been requested.
Kamada (NASDAQ: KMDA) will release its fiscal year and fourth quarter 2025 financial results on Wednesday, March 11, 2026 before U.S. markets open. Management will host an investor conference call at 8:30am Eastern Time the same day and will webcast the discussion live.
Investors may join by phone (U.S.: 1-877-407-0792; Israel: 1-809-406-247; International: 1-201-689-8263) using conference ID 13758519 or via the live webcast link provided by the company.